Literature DB >> 23365135

CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma.

Aikseng Ooi1, Karl Dykema, Asif Ansari, David Petillo, John Snider, Richard Kahnoski, John Anema, David Craig, John Carpten, Bin-Tean Teh, Kyle A Furge.   

Abstract

Sustained activation of the stress-regulated transcription factor NRF2 (NFE2L2) is a prominent feature of many types of cancer, implying that mutations driving NRF2 may be important to tumor progression. In hereditary type 2 papillary renal cell carcinoma (PRCC2, also known as hereditary leiomyomatosis and renal cell cancer), NRF2 activation is a direct consequence of the accumulation of intracellular fumarate, a result of fumarate hydratase (FH) inactivation, but it is not clear how NRF2 may be activated in sporadic forms of PRCC2. Here we show that somatic mutations in NRF2, CUL3, and SIRT1 are responsible for driving the NRF2 activation phenotype in sporadic PRCC2. Transcriptome sequencing revealed the expression pattern of mutant alleles of NRF2, CUL3, and SIRT1 and also confirmed NRF2 activation in clinical specimens. Our results show a convergence in somatic mutations in sporadic PRCC2 with FH mutation in hereditary PRCC2. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23365135     DOI: 10.1158/0008-5472.CAN-12-3227

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  59 in total

1.  Brusatol overcomes chemoresistance through inhibition of protein translation.

Authors:  Bryan Harder; Wang Tian; James J La Clair; Aik-Choon Tan; Aikseng Ooi; Eli Chapman; Donna D Zhang
Journal:  Mol Carcinog       Date:  2017-02-08       Impact factor: 4.784

Review 2.  Mechanisms of NRF2 activation to mediate fetal hemoglobin induction and protection against oxidative stress in sickle cell disease.

Authors:  Xingguo Zhu; Aluya R Oseghale; Lopez H Nicole; Biaoru Li; Betty S Pace
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-23

3.  New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease.

Authors:  Ramaprasad Srinivasan; Christopher J Ricketts; Carole Sourbier; W Marston Linehan
Journal:  Clin Cancer Res       Date:  2015-01-01       Impact factor: 12.531

4.  Hyperkalemic hypertension-associated cullin 3 promotes WNK signaling by degrading KLHL3.

Authors:  James A McCormick; Chao-Ling Yang; Chong Zhang; Brittney Davidge; Katharina I Blankenstein; Andrew S Terker; Bethzaida Yarbrough; Nicholas P Meermeier; Hae J Park; Belinda McCully; Mark West; Aljona Borschewski; Nina Himmerkus; Markus Bleich; Sebastian Bachmann; Kerim Mutig; Eduardo R Argaiz; Gerardo Gamba; Jeffrey D Singer; David H Ellison
Journal:  J Clin Invest       Date:  2014-09-24       Impact factor: 14.808

5.  Hypoxia-responsive microRNA-101 promotes angiogenesis via heme oxygenase-1/vascular endothelial growth factor axis by targeting cullin 3.

Authors:  Ji-Hee Kim; Kwang-Soon Lee; Dong-Keon Lee; Joohwan Kim; Su-Nam Kwak; Kwon-Soo Ha; Jongseon Choe; Moo-Ho Won; Byung-Ryul Cho; Dooil Jeoung; Hansoo Lee; Young-Guen Kwon; Young-Myeong Kim
Journal:  Antioxid Redox Signal       Date:  2014-07-29       Impact factor: 8.401

6.  Dynamic changes in intracellular ROS levels regulate airway basal stem cell homeostasis through Nrf2-dependent Notch signaling.

Authors:  Manash K Paul; Bharti Bisht; Daphne O Darmawan; Richard Chiou; Vi L Ha; William D Wallace; Andrew T Chon; Ahmed E Hegab; Tristan Grogan; David A Elashoff; Jackelyn A Alva-Ornelas; Brigitte N Gomperts
Journal:  Cell Stem Cell       Date:  2014-06-19       Impact factor: 24.633

Review 7.  The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases.

Authors:  Prashant Deshmukh; Sruthi Unni; Gopinatha Krishnappa; Balasundaram Padmanabhan
Journal:  Biophys Rev       Date:  2016-12-06

Review 8.  Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target.

Authors:  Shaohua Ma; Chorlada Paiboonrungruan; Tiansheng Yan; Kevin P Williams; M Ben Major; Xiaoxin Luke Chen
Journal:  Ann N Y Acad Sci       Date:  2018-05-11       Impact factor: 5.691

Review 9.  Precision medicine from the renal cancer genome.

Authors:  Yasser Riazalhosseini; Mark Lathrop
Journal:  Nat Rev Nephrol       Date:  2016-10-03       Impact factor: 28.314

Review 10.  Filtering through the role of NRF2 in kidney disease.

Authors:  Cody J Schmidlin; Matthew B Dodson; Donna D Zhang
Journal:  Arch Pharm Res       Date:  2019-08-01       Impact factor: 4.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.